Upstream Bio, Inc. (UPB)
NASDAQ:UPB
UPB Stock Chart & Stats
$30.30
$0.36(1.20%)
At close: 4:00 PM EST
$30.30
$0.36(1.20%)
Day’s Range― - ―
52-Week Range$7.22 - $33.68
Previous CloseN/A
Volume30.66K
Average Volume (3M)388.50K
Market Cap
$570.87M
Enterprise Value$456.41M
Total Cash (Recent Filing)$341.51M
Total Debt (Recent Filing)$1.27M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
May 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding54,419,987
10 Day Avg. Volume473,530
30 Day Avg. Volume388,499
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)4.30
Price to Sales (P/S)512.30
P/FCF Ratio-10.97
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue159.92
Enterprise Value/Gross Profit165.01
Enterprise Value/Ebitda-2.92
Forecast
1Y Price Target
$43.75Price Target Upside44.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.94
Revenue Forecast (FY)$1.41M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAnalyst notes advancement of the lead respiratory drug into Phase 3 with a planned higher quarterly dose informed by refined modeling using a larger patient dataset, which may improve efficacy in target indications.
Pharmacology And ImmunogenicityIntegrated exposure‑response analyses suggest near-complete target coverage at higher exposure, and observed low anti-drug antibody titers did not reduce clinical efficacy, strengthening the drug's overall clinical profile.
Physician AdoptionA majority of surveyed high-volume allergy and pulmonology physicians indicated they would be likely to prescribe the drug and viewed the lower-dose regimen as comparable or superior to an approved therapy, supporting potential commercial uptake.
Bears Say
Clinical Uncertainty And Data InterpretationVariability in analysis methods and a meaningful portion of placebo patients requiring rescue therapy materially affect interpretation of efficacy, while uncertainty around Phase 3 dosing plans and a multi-year timeline to pivotal results reduce near-term catalyst visibility.
CompetitionSanofi's bispecific nanobody met primary and key secondary endpoints in asthma and chronic rhinosinusitis, increasing competitive pressure and raising the bar for differentiation in the same therapeutic space.
Financial PositionOperating expenses have exceeded analyst expectations and the cash runway is limited relative to cash burn, creating potential financing risk for pursuing multiple late-stage trials.
Upstream Bio, Inc. News
UPB FAQ
What was Upstream Bio, Inc.’s price range in the past 12 months?
Upstream Bio, Inc. lowest stock price was $7.22 and its highest was $33.68 in the past 12 months.
What is Upstream Bio, Inc.’s market cap?
Upstream Bio, Inc.’s market cap is $570.87M.
When is Upstream Bio, Inc.’s upcoming earnings report date?
Upstream Bio, Inc.’s upcoming earnings report date is May 12, 2026 which is in 28 days.
How were Upstream Bio, Inc.’s earnings last quarter?
Upstream Bio, Inc. released its earnings results on Mar 18, 2026. The company reported -$0.78 earnings per share for the quarter, missing the consensus estimate of -$0.735 by -$0.045.
Is Upstream Bio, Inc. overvalued?
According to Wall Street analysts Upstream Bio, Inc.’s price is currently Undervalued.
Does Upstream Bio, Inc. pay dividends?
Upstream Bio, Inc. does not currently pay dividends.
What is Upstream Bio, Inc.’s EPS estimate?
Upstream Bio, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Upstream Bio, Inc. have?
Upstream Bio, Inc. has 54,419,987 shares outstanding.
What happened to Upstream Bio, Inc.’s price movement after its last earnings report?
Upstream Bio, Inc. reported an EPS of -$0.78 in its last earnings report, missing expectations of -$0.735. Following the earnings report the stock price went down -10.762%.
Which hedge fund is a major shareholder of Upstream Bio, Inc.?
Currently, no hedge funds are holding shares in UPB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Upstream Bio, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.75 (44.39% Upside)
$43.75 (44.39% Upside)
Hedge Fund Trend
Increased
By 141.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $46.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.2%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.21%
12-Months-Change
Fundamentals
Return on Equity
-36.48%
Trailing 12-Months
Asset Growth
-26.56%
Trailing 12-Months
Company Description
Upstream Bio, Inc.
Upstream Bio, Inc. (UPB) is a biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. The company operates primarily in the biopharmaceutical sector, specializing in the research and development of novel treatments for various diseases, particularly in the fields of oncology and autoimmune disorders. Upstream Bio aims to leverage its proprietary technology platform to advance its pipeline of drug candidates, ultimately seeking to improve patient outcomes through targeted therapies.
UPB Stock 12 Month Forecast
Average Price Target
$43.75
▲(44.39% Upside)
Technical Analysis
Theravance Biopharma
―
Bicycle Therapeutics
―
Prime Medicine, Inc.
―
Bicara Therapeutics Inc.
―
Zenas BioPharma, Inc.
―
Ownership Overview
8.75% Insiders
19.29% Mutual Funds
44.29% Other Institutional Investors
18.23% Public Companies and
Individual Investors